Aurinia Closing In On Lupus Nephritis With Voclosporin
Phase III AURORA Study Reports Positive Top-Line Data
Executive Summary
Canada’s Aurinia Pharmaceuticals expects to file a US NDA in the first half of next year on the use of its next-generation calcineurin inhibitor, voclosporin, in lupus nephritis, a condition with no approved therapies.
You may also be interested in...
Aurinia Launches Its First Drug With Lupkynis Approval For Lupus Nephritis
The calcineurin inhibitor, only the second drug to be approved by the US FDA for lupus nephritis, will be competing against GlaxoSmithKline’s Benlysta.
Aurinia Suspends Voclosporin Development For Dry Eye, Staying Focused On Lupus
Biotech doesn’t shut the door on returning to ophthalmic formulation of the calcineurin inhibitor in dry eye but puts primary focus on oral voclosporin in lupus nephritis, with an FDA approval decision imminent.
Keeping Track: J&J Submits Ponesimod NDA For MS; US FDA Clears Epclusa For Pediatric HCV
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.